NEON THERAPEUTICS, INC. Research and Development Expense
NEON THERAPEUTICS, INC. reported Research and Development Expense of $9.45 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-01.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-05-01
- NEON THERAPEUTICS, INC. research and development expense for the quarter ending 2020-03-31 was $9.45M, a 41.59% decline year-over-year.
- NEON THERAPEUTICS, INC. research and development expense for the quarter ending 2019-12-31 was $12.69M, a 29.58% decline year-over-year.
- NEON THERAPEUTICS, INC. research and development expense for the quarter ending 2019-09-30 was $14.12M, a 2.22% decline year-over-year.
- NEON THERAPEUTICS, INC. research and development expense for the quarter ending 2019-06-30 was $16.73M, a 13.04% increase year-over-year.
- NEON THERAPEUTICS, INC. research and development expense for fiscal 2019 was $59.72M, a 1.17% decline from fiscal 2018.
- NEON THERAPEUTICS, INC. research and development expense for fiscal 2018 was $60.42M, a 62.45% increase from fiscal 2017.
- NEON THERAPEUTICS, INC. research and development expense for fiscal 2017 was $37.20M, a 89.07% increase from fiscal 2016.
- NEON THERAPEUTICS, INC. research and development expense for fiscal 2016 was $19.67M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2020-03-31 | $9.45M 10-Q · filed 2020-05-01 | $22.14M derived: sum of 2 quarters · filed 2020-05-01 | $36.26M derived: sum of 3 quarters · filed 2020-05-01 | $52.99M derived: sum of 4 quarters · filed 2020-05-01 |
| 2019-12-31 | $12.69M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $26.81M derived: sum of 2 quarters · filed 2020-03-02 | $43.55M derived: sum of 3 quarters · filed 2020-03-02 | $59.72M 10-K · filed 2020-03-02 |
| 2019-09-30 | $14.12M 10-Q · filed 2019-11-12 | $30.86M derived: sum of 2 quarters · filed 2019-11-12 | $47.03M 10-Q · filed 2019-11-12 | $65.05M derived: sum of 4 quarters · filed 2020-05-01 |
| 2019-06-30 | $16.73M 10-Q · filed 2019-08-06 | $32.91M 10-Q · filed 2019-08-06 | $50.93M derived: sum of 3 quarters · filed 2020-05-01 | $65.37M derived: sum of 4 quarters · filed 2020-05-01 |
| 2019-03-31 | $16.17M 10-Q · filed 2020-05-01 | $34.19M derived: sum of 2 quarters · filed 2020-05-01 | $48.63M derived: sum of 3 quarters · filed 2020-05-01 | $63.44M derived: sum of 4 quarters · filed 2020-05-01 |
| 2018-12-31 | $18.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $32.46M derived: sum of 2 quarters · filed 2020-03-02 | $47.27M derived: sum of 3 quarters · filed 2020-03-02 | $60.42M 10-K · filed 2020-03-02 |
| 2018-09-30 | $14.44M 10-Q · filed 2019-11-12 | $29.25M derived: sum of 2 quarters · filed 2019-11-12 | $42.40M 10-Q · filed 2019-11-12 | $53.32M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $14.80M 10-Q · filed 2019-08-06 | $27.96M 10-Q · filed 2019-08-06 | $38.88M derived: sum of 3 quarters · filed 2019-08-06 | $50.41M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $13.16M 10-Q · filed 2019-05-13 | $24.08M derived: sum of 2 quarters · filed 2019-05-13 | $35.61M derived: sum of 3 quarters · filed 2019-05-13 | $42.94M derived: sum of 4 quarters · filed 2019-05-13 |
| 2017-12-31 | $10.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-11 | $22.45M derived: sum of 2 quarters · filed 2019-03-11 | $29.78M derived: sum of 3 quarters · filed 2019-03-11 | $37.20M 10-K · filed 2019-03-11 |
| 2017-09-30 | $11.53M 10-Q · filed 2018-11-13 | $18.86M derived: sum of 2 quarters · filed 2018-11-13 | $26.27M 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $7.33M 10-Q · filed 2018-08-06 | $14.74M 10-Q · filed 2018-08-06 | ||
| 2016-12-31 | $19.67M 10-K · filed 2019-03-11 |